https://mtorsignaling.com/inde....x.php/behavior-of-qu
Patients in the CTLA-4i group were more frequently seropositive along with greater amounts of comorbidities. At 6 and 12 months, clients into the IL6Ri team had a lower life expectancy DAS28 rating compared to TNFi monotherapy. Those on CTLA-4i monotherapy also had a lower life expectancy DAS28 rating at 6 months than the TNFi team, although differences were lost by 12 months. Medicine retention at 18 months was highest into the IL6Ri supply (68%) and CTLA-4i supply (80%) compared with just 55%
Like
Comment
Share
